Abstract
DiaPep277 is an immunomodulatory peptide that arrests beta cell destruction in mouse models of type 1 diabetes mellitus (T1DM). This article extends an original pilot observation to two studies of 61 patients (age > 16 years), diagnosed with T1DM within 6 months, and with measurable beta cell function. Patients were treated with placebo (n = 27) or 1.0 mg DiaPep277 (n = 34). After 13 months, 1.0 mg Dia Pep277 treatment significantly (P = 0.02) preserved beta cell function as compared to the control with a trend for reduced HbA1c. This was achieved without an increase in insulin dose in the DiaPep277 group and with excellent safety. DiaPep277-treated patients also had fewer Th1 DiaPep277-specific T cells.
MeSH terms
-
Amino Acid Sequence
-
Area Under Curve
-
C-Peptide / blood
-
Chaperonin 60
-
Diabetes Mellitus, Type 1 / blood
-
Diabetes Mellitus, Type 1 / diagnosis
-
Diabetes Mellitus, Type 1 / drug therapy*
-
Diabetes Mellitus, Type 1 / immunology
-
Female
-
Follow-Up Studies
-
Glycated Hemoglobin / analysis
-
Humans
-
Hypoglycemic Agents / metabolism*
-
Insulin / biosynthesis*
-
Insulin-Secreting Cells / metabolism
-
Male
-
Molecular Sequence Data
-
Peptide Fragments / adverse effects
-
Peptide Fragments / chemistry
-
Peptide Fragments / therapeutic use*
-
Peptides / adverse effects
-
Peptides / chemistry
-
Peptides / therapeutic use*
-
Time Factors
-
Treatment Outcome
Substances
-
C-Peptide
-
Chaperonin 60
-
DiaPep 277
-
Glycated Hemoglobin A
-
Hypoglycemic Agents
-
Insulin
-
Peptide Fragments
-
Peptides